Tiziana Life Sciences PLC (TLSA) is a late-stage biotherapeutics enterprise focused on the development of groundbreaking therapeutics. The company’s nasal, and oral therapies have an edge over intravenous delivery. Two lead product candidates of the company include intranasal foralumab and milciclib.
The price of TLSA stock during the early trading of March 10, 2022, was last checked to be $0.96 with a vertical gain of 25.27%.
TLSA: Events and Happenings
On March 10, 2022, TLSA reported optimistic clinical results in the treatment of Secondary Progressive Multiple Sclerosis, following the conclusion of six months of dosage with foralumab. Biological and clinical developments were observed in the patient along with good tolerability using the company’s innovative immunotherapeutics.
On March 01, 2022, TLSA updated on its publication of data of the highly prognostic potential of StemPrintER for risk of distant reappearance in breast cancer patients in the European Journal of Cancer. On February 10, 2022, TLSA announced its Executive management’s participation at the Virtual BIO CEO & Investor Conference 2022 held on February 14-15, 2022.
On February 04, 2022, TLSA informed the press about the modified submission of IND application of foralumab to the FDA for its assessment in patients with Crohn’s Disease.
TLSA: Key Financials
On September 24, 2021, TLSA reported its interim financial statement for the first half of 2021 ended June 30, 2021. Some of the key aspects are as follows.
EPS
Basic and diluted loss attributed to the equity owners per share in H1 2021 was reported to be £12.5 million or 7.4 pence comparable to £3.91 million or 2.6 pence in the same half of 2020. The company noted a considerable gain in its loss over the year.
Conclusion
TLSA stock dropped by 82% from the past year as the pandemic laid the financial conditions down globally. Recently, in the early trading, the company’s stock showed signs of improvement as it proclaimed positive clinical outcomes for foralumab.
